Dissociation Between the Potent β-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine

  • Nigel H. Greig
  • Tada Utsuki
  • Qian-sheng Yu
  • Harold W. Holloway
  • Tracyann Perry
  • David Tweedie
  • Tony Giordano
  • George M. Alley
  • De-Mao Chen
  • Mohammad A. Kamal
  • Jack T. Rogers
  • Kumar Sambamurti
  • Debomoy K. Lahiri
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Cholinesterase Inhibitor Human Neuroblastoma Cell Anticholinesterase Activity Human AChE Tricyclic Ring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–356.PubMedCrossRefGoogle Scholar
  2. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol Med (2002;1:1–31.CrossRefGoogle Scholar
  3. Lahiri DK, Farlow MR, Greig NH, et al. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003;4(2):97–112.PubMedCrossRefGoogle Scholar
  4. Sambamurti K, Granholm AC, Kindy MS, et al. Cholesterol and Alzheimer’s disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 2004;5(6):517–528.PubMedCrossRefGoogle Scholar
  5. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11(2):131–145.PubMedCrossRefGoogle Scholar
  6. DeKosky ST. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 2003;51(5 Suppl Dementia):S314–S320.PubMedCrossRefGoogle Scholar
  7. Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2004;10(25):3111–3119.PubMedCrossRefGoogle Scholar
  8. Farlow MR. Utilizing combination therapy in the treatment of Alzheimer's disease. Expert Rev Neurother 2004;4(5):799–808.PubMedCrossRefGoogle Scholar
  9. Pietrzik C, Behl C. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Pathol 2005;86(3):173–185.PubMedCrossRefGoogle Scholar
  10. Marlatt MW, Webber KM, Moreira PI, et al. Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr Med Chem 2005;12(10):1137–1147.PubMedCrossRefGoogle Scholar
  11. Standridge JB. Current status and future promise of pharmacotherapeutic strategies for Alzheimer's disease. J Am Med Dir Assoc 2005;6(3):194–199.PubMedCrossRefGoogle Scholar
  12. Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004;2(4):303–312.PubMedCrossRefGoogle Scholar
  13. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002;16(12):811–824.PubMedCrossRefGoogle Scholar
  14. Greig NH, Pei XF, Soncrant TT, et al. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995;15(1):3–31.PubMedCrossRefGoogle Scholar
  15. Greig NH, De Micheli E, Holloway HW, et al. The experimental Alzheimer drug phenserine: pharmacokinetics and pharmacodynamics in the rat. Acta Neurol Scand 2000;176:74–84.CrossRefGoogle Scholar
  16. Greig NH, Sambamurti K, Yu QS, et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimers Res 2005;2:281–291.CrossRefGoogle Scholar
  17. Lahiri D, Chen D, Vivien D, et al. The role of cytokines in the gene expression of amyloid β-protein precursor: identification of a 5′UTR binding nuclear factor and its implications for Alzheimer's disease. J Alzheimer Dis 2003;5:81–90.Google Scholar
  18. Lahiri DK, Farlow MR, Hintz N, et al (2000) Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol Scand 2000;176:60–67.CrossRefGoogle Scholar
  19. Lahiri DK, Farlow MR, Sambamurti K. (1998) The secretion of amyloid beta-peptide is inhibited in tacrine-treated human neuroblastoma cells. Mol Brain Res 1998;62:131–140.PubMedCrossRefGoogle Scholar
  20. Lahiri DK, Farlow MR. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci 1996;7(1):41–49.PubMedCrossRefGoogle Scholar
  21. Yu QS, Greig NH, Holloway HW, Brossi A. Syntheses and anticholinesterase activities of (3aS)-N(1), N(8)-bisnorphenserine(3aS)-N(1), N(8)-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine. J Med Chem 1998;41:2371–2379.PubMedCrossRefGoogle Scholar
  22. Yu QS, Holloway HW, Utsuki T, et al. Phenserine-based synthesis of novel selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 1999;42:1855–1861.PubMedCrossRefGoogle Scholar
  23. Yu QS, Holloway HW, Flippen-Anderson F, et al. Methyl analogues of the experimental Alzheimer drug, phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 2001;44:4062–4071.PubMedCrossRefGoogle Scholar
  24. Yu QS, Zhu X, Holloway HW, et al. Anticholinesterase activity of compounds related to geneserine tautomers―N-oxides and 1,2-oxazines. J Med Chem 2002;45:3684–3691.PubMedCrossRefGoogle Scholar
  25. Luo X, Yu QS, Zhan M, et al. Novel anticholinesterases based on the molecular skeletons of furobenzofuran and benzodioxepine. J Med Chem 2005;48(4):986–994.PubMedCrossRefGoogle Scholar
  26. Haroutunian V, Greig NH, Utsuki T, et al. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Mol Brain Res 1997;46:161–168.PubMedCrossRefGoogle Scholar
  27. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002;14:77–91.PubMedCrossRefGoogle Scholar
  28. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci. USA, 2005;102:17213–8.PubMedCrossRefGoogle Scholar
  29. Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2001;2:CD001499.PubMedGoogle Scholar
  30. Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 2001;98(13):7605–7610.PubMedCrossRefGoogle Scholar
  31. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277(47):45518–45528.PubMedCrossRefGoogle Scholar
  32. Venti A, Giordano T, Eder P, et al. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region. Ann N Y Acad Sci. 2004;1035:34–44.Google Scholar
  33. Maloney B, Ge YW, Greig NH, Lahiri DK. Presence of a “CAGA box” in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. FASEB J 2004;18(11):1288–1290.PubMedGoogle Scholar
  34. Patel N, Spangler E, Greig NH, et al. Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the NMDA receptor. Neuroreport 1998;9:171–176.PubMedCrossRefGoogle Scholar
  35. Greig NH. Drug entry to the brain and its pharmacologic manipulation. In, Handb Exp Pharmacol 1992;103:487–523.Google Scholar
  36. Greig NH, Yu QS, Utsuki T, et al. Optimizing drugs for brain action. In: Koliber D, Lustig S, Shapira S (eds) Blood-Brain Barrier Drug Delivery and Brain Pathology. New York: Kluwer Academic/Plenum, 2002, pp 281–309.Google Scholar
  37. Thal LJ. Therapeutics and mild cognitive impairment: current status and future directions. Alzheimer Dis Assoc Disord 2003;17(suppl 2):S69–S71.Google Scholar
  38. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003;28(3-4):515–522.PubMedCrossRefGoogle Scholar
  39. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363(9427):2105–2115.PubMedCrossRefGoogle Scholar
  40. Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83–87.PubMedCrossRefGoogle Scholar
  41. Greig NH, Mattson MP, Perry T, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-α inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004;1035:290–315.PubMedCrossRefGoogle Scholar
  42. Cole GM, Morihara T, Lim GP, et al. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann N Y Acad Sci 2004;1035:68–84.PubMedCrossRefGoogle Scholar
  43. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892–5901.PubMedCrossRefGoogle Scholar
  44. Hoglund K, Thelen KM, Syversen S, et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19(5-6):256–266.PubMedCrossRefGoogle Scholar
  45. Doraiswamy PM, Steffens DC, McQuoid DR. Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer's disease: a pilot observational study. Am J Alzheimers Dis Other Demen 2004;19(5):275–278PubMedCrossRefGoogle Scholar
  46. Ritchie CW, Bush AI, Masters CL. Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin Invest Drugs 2004;13(12):1585–1592.CrossRefGoogle Scholar
  47. Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol Aging 2004;25(5):651–660.PubMedCrossRefGoogle Scholar
  48. Greig NH, Sambamurti K, Yu QS, et al. Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease. In: Giacobini E (ed) Butyrylcholinesterase: Its Function and Inhibition. London: Martin Dunitz, 2003, pp 69–90.Google Scholar
  49. Soreq H, Seidman S. Acetylcholinesterase―new roles for an old actor. Nat Rev Neurosci 2001;2:294–302.PubMedCrossRefGoogle Scholar
  50. Massoulie J. Molecular forms and anchoring of acetylcholinesterase. In: Giacobini E (ed) Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz, 2000, pp 81–102.Google Scholar
  51. Soreq H, Gnatt A, Loewenstein Y, Neville LF. Excavations into the active-site gorge of cholinesterases. Trends Biochem Sci 1992;17:353–358.PubMedCrossRefGoogle Scholar
  52. Dvir H, Wong DM, Harel M, et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Biochemistry 2002;41:2970–2981.PubMedCrossRefGoogle Scholar
  53. Silman I, Millard CB, Ordentlich A, et al. A preliminary comparison of structural models for catalytic intermediates of acetylcholinesterase. Chem Biol Interact 1999;May 14:119–120.Google Scholar
  54. Silman I, Harel M, Axelsen P, et al. Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents. Biochem Soc Trans 1994;22:745–749.PubMedGoogle Scholar
  55. Inestrosa NC, Sagal JP, Colombres M. Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell Biochem 2005;38:299–317.PubMedGoogle Scholar
  56. Nitsch RM, Farber SA, Growdon JH, Wurtman RJ. Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci U S A 1993;90(11):5191–5193.PubMedCrossRefGoogle Scholar
  57. Muller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 1997;60(13-14):985–991.PubMedCrossRefGoogle Scholar
  58. Buxbaum JD, Greengard P. Regulation of APP processing by intra- and intercellular signals. Ann N Y Acad Sci 1996;777:327–331.PubMedCrossRefGoogle Scholar
  59. Desdouits-Magnen J, Desdouits F, Takeda S, et al. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J Neurochem 1998;70(2):524–530.PubMedGoogle Scholar
  60. Utsuki T, Shoaib M, Lahiri DK, et al. Nicotine reduces the secretion of Alzheimer's ß-Amyloid precursor protein containing ß-Amyloid peptide in the rat. J Alzheimers Dis 2002;4:405–415.PubMedGoogle Scholar
  61. Lahiri DK, Utsuki T, Chen D, et al. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. Ann N Y Acad Sci 2002;965:364–372.PubMedCrossRefGoogle Scholar
  62. Yu QS, Luo W, Holloway HW, et al. Racemic N1-norphenserine and its enantiomers: unpredicted inhibition of acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro. Heterocycles 2003;61:529–539.CrossRefGoogle Scholar
  63. Munoz FJ, Aldunate R, Inestrosa NC. Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. Neuroreport 1999;10(17):3621–3625.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Nigel H. Greig
    • 1
  • Tada Utsuki
  • Qian-sheng Yu
  • Harold W. Holloway
  • Tracyann Perry
  • David Tweedie
  • Tony Giordano
  • George M. Alley
  • De-Mao Chen
  • Mohammad A. Kamal
  • Jack T. Rogers
  • Kumar Sambamurti
  • Debomoy K. Lahiri
  1. 1.Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research ProgramNational Institute on AgingBaltimoreUSA

Personalised recommendations